Venture capitalists are now creating the startups themselves

By most industry counts, at least 90 percent of startups ultimately fail. For digital health startups, the figure climbs to an even grimmer 98 percent. That failure rate has barely moved in twenty years, despite accelerators, lean methodology, and a decade of abundant capital.

The venture studio model is Silicon Valley’s newest answer to that bleak statistical reality: handpick the founding team and build the company in-house. Pointing to data that shows studio-born startups are roughly 30% more likely to reach the Series A milestone than traditional startups, leaders in the sector see the model as a way to protect their investment by minimizing risk and maximizing the company’s chances of success. 

Venture studios are distinct from the things they’re often confused with. An accelerator takes existing startups and runs them through a program. A VC fund writes a check and takes a board seat. A studio originates the idea in-house, builds the initial product with its own team, recruits a founding CEO to run it and seeds it with its own capital. It retains, by most surveys, somewhere between 20 and 40 percent of the resulting company, and sometimes considerably more.

The pitch is compelling and the supporting numbers are eye-catching: studio-built companies reportedly reach Series A in roughly half the time, with seed funding rates north of 80 percent. Those figures deserve an asterisk. They come largely from studio-affiliated research and industry associations with an obvious interest in the answer, and they sit uneasily beside a less-quoted statistic — that roughly 70 percent of venture studios themselves fail.

Studios in the age of AI

AI and healthcare is a natural fit for the venture studio model, though one where measure and caution are essential.

The sector's failure modes are exactly the ones a studio claims to solve. Healthcare AI startups can often fail on regulatory misreads, lack of market understanding and not exercising enough foresight. More often than not, these are issues of institutional knowledge. A studio with genuine operating scar tissue can, in principle, hand a first-time founder the roadmap to avoid those pitfalls.

Revolution Venture Studios, owned by digital health founder-entrepreneur Kyle Robertson, focuses on improving the healthcare system’s most entrenched problems with targeted and human-guided AI optimization.

Inside RVS

Revolution Venture Studios describes itself less as a fund than as a startup bootcamp: seed financing, product development, and operational mentorship, with portfolio companies run day-to-day by co-founders who serve as CEO while Robertson retains a founding stake. Its stated mission is to "build companies that change the world for the better," and its ambitions are set on lauching future unicorns.

The portfolio is tightly clustered around personal health and its adjacent economics:

• Amara, a roll-up serving medspa owners with backend operations, growth strategy, and acquisition support — a consolidation play on a fragmented, largely cash-pay corner of aesthetics.
• Bioverse, a direct-to-consumer telehealth platform focusing on longevity and wellness.
• CareBeam, an ambient clinical documentation tool that transcribes patient-clinician conversations into SOAP notes for provider review and sign-off.

CareBeam is a calculated bet on the inevitable AI overhaul of traditional healthcare systems and processes. But with the rapid disruption comes a dose of reasonable apprehension. The health systems getting the most value from ambient AI have converged around some standard guidelines and guardrails. Patients should be asked upfront for their consent for a machine to listen in on the visit. The clinician should review and approve every note before it goes into the patient record.

What should a prospective founder ask?

For an entrepreneur weighing a studio offer, it is important to pose the right questions to get the full picture:

What exactly am I getting from the studio? The deal could be a simple investment or come with a formed C-suite, employees, mentorship and investor contacts.

Whose regulatory posture governs? In a studio-built company, the compliance defaults are often inherited from the studio.

What happens when I disagree? A founding CEO with a minority stake and a studio-appointed board has less room than the title might imply.

What is the studio's own runway? Get assurance that you’re founding a company with a stable and solvent partner.

The bottom line

The venture studio is a genuinely promising answer to healthtech's failure arithmetic. But the model's central premise — that concentrated operating experience produces better companies — carries a corollary the sector rarely says out loud. Concentrated experience only helps if the experience being concentrated is the right kind.

The venture studio model represents a broader shift in how startups are conceived and built. Rather than treating entrepreneurship as a solitary act of founder intuition, studios turn company creation into a repeatable process that combines capital, talent, technology and institutional knowledge under one roof.

That may make startups faster and more efficient to launch, but it also raises a fundamental question: does standardizing venture creation improve the odds of building enduring companies, or simply make it easier to produce more companies? The answer may depend less on how quickly a studio can incubate a startup than on whether it can identify the right problems to solve and build businesses that can grow and flourish out on their own.